Clinical Trial Update: Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial update evaluating apatinib in combination with a CDK4/6 inhibitor as first-line therapy for HR+/HER2- breast cancer (SNF4 subty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Apatinib (apatinib)
• CDK4/6 inhibitor

Snippet

Sponsor: Fudan University | Conditions: Advanced Breast Cancer, HR+/HER2- Breast Cancer | Phase 3 | Status: RECRUITING